Health Affairs, 25, no. 3 (2006): 707-719 doi: 10.1377/hlthaff.25.3.707 © 2006 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donohue, J. Search for Related Content PubMed PubMed Citation Articles by Donohue, J. Related Collections Access To Care Health Reform Legal/Regulatory Issues Managed Care - Medicare Medicare Business Of Health Mental Health/Substance Abuse Pharmaceuticals Chronic Care Health Spending Consumer Issues Elderly

Regulation & Policy

Mental Health In The Medicare Part D Drug Benefit: A New Regulatory Model?

The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 represents the most significant expansion of Medicare benefits since the program’s inception and has important implications for mental health. Medicare will become a major payer for psychotropic medications through the new prescription drug benefit. The structure of the drug benefit’s delivery system creates incentives for plans to underprovide medications, like psychotropic drugs, that are used persistently and are associated with high expected costs. Regulators have put policies in place to counteract these incentives. This paper examines these strategies’ likely success and suggests additional approaches to be considered.

                      What's this?

This article has been cited by other articles:

				J. M. Donohue, H. A. Huskamp, and S. H. Zuvekas Dual Eligibles With Mental Disorders And Medicare Part D: How Are They Faring? Health Aff., May 1, 2009; 28(3): 746 - 759. [Abstract] [Full Text] [PDF]

				J. C. West, J. E. Wilk, I. L. Muszynski, D. S. Rae, M. Rubio-Stipec, C. L. Alter, W. E. Narrow, and D. A. Regier Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First 4 Months of the Medicare Prescription Drug Benefit Am J Psychiatry, May 1, 2007; 164(5): 789 - 796. [Abstract] [Full Text] [PDF]

				J. M. Rosenberg Overview of Medicare Part D prescription drug benefit: Potential implications for patients with psychotic disorders Am. J. Health Syst. Pharm., January 15, 2007; 64(2_Supplement_1): S18 - S23. [Abstract] [Full Text] [PDF]